|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
DE69603615T2
(de)
*
|
1995-10-10 |
2000-02-17 |
Pfizer Inc., New York |
Nk-1 rezeptor antagonisten in neurogener entzündung in gen-therapie
|
|
US20030219863A1
(en)
*
|
1997-01-31 |
2003-11-27 |
Bristol-Myers Squibb Company |
Soluble CTLA4 mutant molecules and uses thereof
|
|
US7094874B2
(en)
*
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
SI1935427T1
(en)
*
|
2000-07-03 |
2018-05-31 |
Bristol-Myers Squibb Company |
USE OF HEATED CTLA4 MUTANT MOLECULES
|
|
HUP0303930A3
(en)
*
|
2001-01-26 |
2012-09-28 |
Univ Emory |
Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
|
|
PL204899B1
(pl)
|
2001-05-23 |
2010-02-26 |
Bristol Myers Squibb Co |
Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
|
|
US20030086903A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
|
WO2003092624A2
(en)
*
|
2002-05-02 |
2003-11-13 |
University Of Connecticut Health Center |
Use of heat shock proteins to enhance efficacy of antibody therapeutics
|
|
EP2168603A1
(en)
*
|
2003-11-14 |
2010-03-31 |
GenVec, Inc. |
Therapeutic regimen for treating cancer
|
|
WO2007120542A2
(en)
*
|
2006-03-30 |
2007-10-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid library and aav capsid proteins
|
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
KR101378872B1
(ko)
|
2006-09-26 |
2014-04-11 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
합성 애주번트를 함유하는 백신 조성물
|
|
PT2222697E
(pt)
|
2007-11-01 |
2013-02-15 |
Perseid Therapeutics Llc |
Polipeptídeos imunossupressores e ácidos nucleicos
|
|
SI2437753T1
(sl)
|
2009-06-05 |
2016-12-30 |
Infectious Disease Research Institute |
Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
|
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
|
CN103153332A
(zh)
|
2010-09-28 |
2013-06-12 |
卡尔医疗有限公司 |
用于治疗血液恶性肿瘤的组合物和方法
|
|
AU2012243039B2
(en)
|
2011-04-08 |
2017-07-13 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
CN110339160A
(zh)
|
2012-02-07 |
2019-10-18 |
传染性疾病研究院 |
包含tlr4激动剂的改进佐剂制剂及其使用方法
|
|
PT2850431T
(pt)
|
2012-05-16 |
2018-07-23 |
Immune Design Corp |
Vacinas para hsv-2
|
|
EP3711768A1
(en)
|
2013-04-18 |
2020-09-23 |
Immune Design Corp. |
Gla monotherapy for use in cancer treatment
|
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
|
EP4112638A1
(en)
|
2016-05-16 |
2023-01-04 |
Access to Advanced Health Institute |
Formulation containing tlr agonist and methods of use
|
|
KR102748354B1
(ko)
|
2016-06-01 |
2024-12-31 |
액세스 투 어드밴스드 헬스 인스티튜트 |
사이징제를 함유하는 나노명반 입자
|
|
CN111315406A
(zh)
|
2017-09-08 |
2020-06-19 |
传染病研究所 |
包括皂苷的脂质体调配物及其使用方法
|